|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||4.0000 - 4.0100|
|52 Week Range||2.4300 - 6.8400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
S&P; Dow Jones Indices will make the following changes to the S&P; MidCap 400 and S&P; SmallCap 600 effective prior to the open of trading on Thursday, February 13:
BALA CYNWYD, PA / ACCESSWIRE / December 18, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Diplomat Pharmacy, Inc. ("Diplomat" ...
NEW YORK, NY / ACCESSWIRE / December 14, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) in connection with the proposed acquisition of the Company by UnitedHealth Group's (NYSE: UNH) OptumRx. Under the terms of the acquisition agreement, DPLO shareholders will receive $4 per share in cash.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Diplomat Pharmacy, Inc. (NYSE: DPLO) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed sale to UnitedHealth Group Inc.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) relating to the sale of the Company to UnitedHealth Group Incorporated. Under the terms of the Merger, Diplomat shareholders will have the right to receive $4.00 in cash for each Diplomat common stock owned.
3rd Quarter Revenue of $1,301 Million , compared to $1,373 Million , Net Loss of $177 Million , compared to Net Income of $0.2 Million , Adjusted EBITDA of $11.5 Million , compared to $41.9 Million FLINT, ...
FLINT, Mich. , Oct. 30, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) will release its third-quarter 2019 operating results before market open Tuesday, Nov. 12 . A conference call and live ...
FLINT, Mich., Oct. 16, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), effective today, has completed the sale of certain assets of Envoy Health Management, LLC to Diligent Health Solutions, LLC, a multifaceted healthcare communication center. The contracts administered at the Chantilly, Virginia location as well as associated Envoy Health Management employees have been transferred to Diligent Health Solutions. Diplomat is retaining a portion of the Envoy Health Management operations, specifically the portion operated out of the Flint, Michigan location, which will continue to specialize in digital therapeutics and pharmaceutical services.
Following the retirement of Chris Luthin, David Skomo Appointed COO at CastiaRx. FLINT, Mich., Oct. 2, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), has appointed David Skomo as chief operating officer of CastiaRx following the retirement of Chris Luthin. CastiaRx, a division of Diplomat, is a pharmacy benefit manager (PBM) that helps healthcare payers manage specialty pharmacy costs.
2nd Quarter Revenue of $1,288 Million , compared to $1,416 Million , Net Loss of $159.5 Million , compared to a Net Loss of $4.0 Million , Adjusted EBITDA of $19.3 Million , compared to $42.7 Million FLINT, ...
At the direction of its Board of Directors, the company is reviewing strategic alternatives focused on maximizing shareholder value. The strategic alternatives expected to be considered include, but are not limited to, a sale or merger of the Company, continuing to pursue value-enhancing initiatives as a standalone company, capital structure changes, or the sale or other disposition of certain of the Company's businesses or assets. Diplomat has retained Foros Securities LLC as financial advisor and Sidley Austin LLP as legal advisor to assist with its strategic alternatives review.
This innovative agreement forms the nation's first large-scale physician practice-based infusion program. FLINT, Mich., Aug. 8, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), is pleased to announce an exclusive agreement between Diplomat and Allergy Partners, P.A., to manage in-office and in-home delivery and administration of infusion drugs and biologics. Allergy Partners is the nation's largest independent, single-specialty practice for allergic disease, asthma, and immunology.
FLINT, Mich. , July 18, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), will release its second-quarter 2019 operating results before market open Friday, August 9 . A conference call and live ...
SAN DIEGO, July 15, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Diplomat Pharmacy, Inc. ("Diplomat") (DPLO) and certain of its officers. Earlier in 2019 a securities class action lawsuit was filed on behalf of purchasers of the securities of Diplomat from February 26, 2018 through February 21, 2019, (the "Class Period").
The nation's largest independent specialty pharmacy and infusion services provider launches a digital library of resources and tools for patients and caregivers. FLINT, Mich. , July 9, 2019 /PRNewswire/ ...